Indivior's S-4 Lays Out Supernus Merger Terms: $1B Special Dividend, $650M Term Loan, and $125M in Synergies
INDV sits 57% above its 52-week low of $22.22.
Summary
Indivior's S-4 for its merger of equals with Supernus details a $1 billion Special Dividend to Indivior stockholders, a $650 million term loan to fund it, $125 million in expected synergies, and termination fees up to $174 million. The deal is expected to close in Q4 2026 pending HSR clearance and stockholder votes.
Key Events · M&A and Partnerships · INDV
-
Merger of Equals with Supernus
Indivior will acquire Supernus in an all-stock merger at a fixed exchange ratio of 1.5401 Indivior shares per Supernus share. Supernus stockholders will own approximately 43.5% of the combined company, with Indivior stockholders owning 56.5%.
-
$1B Special Dividend to Indivior Stockholders
Indivior will declare a $1 billion Special Dividend payable to Indivior stockholders of record immediately prior to closing, funded by a new $650 million senior secured term loan from Citibank plus available cash.
-
Alternative Dividend Scenario
If the Committed Financing becomes unavailable and no replacement financing is found, Indivior will instead declare a $500 million cash dividend plus $529.5 million in dividend payment rights payable within one year of closing.
-
Termination Fees and Outside Date
Indivior would pay a $174 million termination fee and Supernus would pay $101 million under specified circumstances. The outside date is February 1, 2027, extendable to August 1, 2027 if antitrust clearance is the only outstanding condition.
Analysis · INDV · Life Sciences
This S-4 registration statement serves as the definitive disclosure for the Indivior-Supernus merger of equals announced on August 3, 2026. It introduces material new terms absent from the initial 8-K: a $1 billion Special Dividend to Indivior stockholders funded by a new $650 million senior secured term loan, an Alternative Dividend Scenario if financing fails, termination fees of $174 million (Indivior) and $101 million (Supernus), expected annual cost synergies of $125 million, and detailed pro forma financials showing the combined company would have posted a pro forma net loss of $543 million for 2025. The filing also discloses the HSR waiting period expires September 21, 2026, with closing expected in Q4 2026. For Indivior stockholders, the Special Dividend represents a significant cash return contingent on deal completion; for Supernus stockholders, the fixed exchange ratio of 1.5401 means their consideration value fluctuates with Indivior's stock price, which has declined from $40.01 at announcement to $34.87 today. The pro forma loss reflects substantial purchase accounting adjustments, including $5.4 billion in intangible assets and $1.139 billion in deferred tax liabilities, which will pressure near-term reported earnings.
How filings like this one have moved
In the 30 days to Sep 9, 2026, 44.3% of the 601 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.47%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, INDV was trading at $34.87 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.1B. The 52-week trading range was $22.22 to $42.81. This filing was assessed with neutral market sentiment and an importance score of 9 out of 10.